Full Text View
Tabular View
Study Results
Related Studies
Faslodex in McCune Albright Syndrome (FMAS)
This study is ongoing, but not recruiting participants.
Study NCT00278915   Information provided by AstraZeneca

First Received on January 17, 2006.   Last Updated on September 24, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Puberty, Precocious
McCune-Albright Syndrome
Additional conditions recognized in this trial
Fibrous Dysplasia, Polyostotic
More general conditions related to this trial
Bone Diseases
Bone Diseases, Developmental
Endocrine System Diseases
Fibrous Dysplasia of Bone
Gonadal Disorders
Musculoskeletal Diseases
Osteochondrodysplasias
Interventions listed in this trial
Fulvestrant
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services